Monday, July 3, 2017
Iovance Biotherapeutics, a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, changed its corporate name from Lion Biotechnologies to Iovance Biotherapeutics. The company’s new NASDAQ ticker symbol “IOVA” will be effective at the open of the market on June 28, 2017. The former ticker symbol “LBIO” will remain effective through the market close today, June 27, 2017. The new website for Iovance Biotherapeutics is www.iovance.com.